Cargando…

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

BACKGROUND: Bioinformatically designed mosaic antigens increase the breadth of HIV vaccine-elicited immunity. This study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 vaccine with the previously tested trivalent formulation. METHODS: This randomised, pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baden, Lindsey R, Stieh, Daniel J, Sarnecki, Michal, Walsh, Stephen R, Tomaras, Georgia D, Kublin, James G, McElrath, M Juliana, Alter, Galit, Ferrari, Guido, Montefiori, David, Mann, Philipp, Nijs, Steven, Callewaert, Katleen, Goepfert, Paul, Edupuganti, Srilatha, Karita, Etienne, Langedijk, Johannes P, Wegmann, Frank, Corey, Lawrence, Pau, Maria G, Barouch, Dan H, Schuitemaker, Hanneke, Tomaka, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529856/ https://www.ncbi.nlm.nih.gov/pubmed/33010242 http://dx.doi.org/10.1016/S2352-3018(20)30229-0

Ejemplares similares

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
por: Stieh, Daniel J, et al.
Publicado: (2022)

Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH
por: van Duijn, Janine, et al.
Publicado: (2023)

Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies
por: Vaine, Michael, et al.
Publicado: (2010)

Traversing missing links in the spread of HIV
por: Brintnell, Erin, et al.
Publicado: (2022)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals
por: Edupuganti, Srilatha, et al.
Publicado: (2019)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults
por: Cohen, Kristen W., et al.
Publicado: (2023)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
por: Andersen-Nissen, Erica, et al.
Publicado: (2021)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
por: Huang, Yunda, et al.
Publicado: (2022)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
por: Andersen-Nissen, E, et al.
Publicado: (2012)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities
por: Seaton, Kelly E., et al.
Publicado: (2014)

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination
por: Cram, Jacob A., et al.
Publicado: (2019)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
por: Orrell, Catherine, et al.
Publicado: (2015)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load
por: Janes, Holly, et al.
Publicado: (2012)

HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women
por: Musey, Luwy, et al.
Publicado: (1997)

Dynamics of Viral Evolution and CTL Responses in HIV-1 Infection
por: Liu, Yi, et al.
Publicado: (2011)

Traversing Wounds of the Orbit
por: Greig, David M.
Publicado: (1924)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
por: Churchyard, Gavin, et al.
Publicado: (2016)

Cell free HIV-1 virus can infect inner and outer foreskin polarized explants
por: Lemos, MP, et al.
Publicado: (2012)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
por: Hosseinipour, Mina C, et al.
Publicado: (2020)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

Aggregate complexes of HIV-1 induced by multimeric antibodies
por: Stieh, Daniel J, et al.
Publicado: (2014)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Efficiency of multi-traversal targets
por: Hereward, Hugh G, et al.
Publicado: (1965)

Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection
por: Jacob-Dolan, Catherine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_17kejstj11v0tb6h604uclpbc9